Onconetix Inc
ONCO
Company Profile
Business description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Contact
201 E. Fifth Street
Suite 1900
CincinnatiOH45202
USAT: +1 513 620-4101
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Reassuring organic growth for undervalued ASX share
Efficiency gains are starting to make their mark.
stocks
Big IPOs are enticing but are they good investments?
Historically, buzzy debuts have been painful for buyers.
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,692.80 | 143.80 | -1.63% |
| CAC 40 | 7,927.75 | 152.99 | -1.89% |
| DAX 40 | 24,802.78 | 661.03 | -2.60% |
| Dow JONES (US) | 48,147.33 | 949.73 | -1.93% |
| FTSE 100 | 10,346.34 | 106.34 | -1.02% |
| HKSE | 22,410.80 | 430.82 | -1.89% |
| NASDAQ | 22,617.73 | 1,261.47 | -5.28% |
| Nikkei 225 | 56,436.65 | 3,007.56 | -5.06% |
| NZX 50 Index | 14,107.41 | 139.84 | -0.98% |
| S&P 500 | 6,910.39 | 265.44 | -3.70% |
| S&P/ASX 200 | 8,592.60 | 137.80 | -1.58% |
| SSE Composite Index | 3,533.79 | 43.82 | -1.22% |